$1.03
+0.12 (+13.11%)
Open$0.94
Previous Close$0.91
Day High$1.05
Day Low$0.92
52W High$4.14
52W Low$1.86
Volume—
Avg Volume111.8K
Market Cap13.32M
P/E Ratio46.74
EPS$0.08
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+354.4% upside
Current
$1.03
$1.03
Target
$4.68
$4.68
$2.81
$4.68 avg
$5.27
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.41M | 3.13M | 3.55M |
| Net Income | -181,214 | -134,676 | -196,009 |
| Profit Margin | -5.3% | -4.3% | -5.5% |
| EBITDA | -236,458 | -218,349 | -232,431 |
| Free Cash Flow | -122,360 | -122,296 | -194,300 |
| Rev Growth | +8.9% | +0.4% | +3.6% |
| Debt/Equity | 0.21 | 0.21 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |